AN INSIGHT INTO OPHTHALMIC DRUG DELIVERY SYSTEM
Abstract
Promising management of eye ailments take off effective concentration of drug at the eye for sufficient period of time. Dosage forms are administered directly to eye for localized ophthalmic therapy. Most of the treatments call for the topical administration of ophthalmic active drugs to the tissues around the ocular cavity. Conventional ophthalmic drug delivery systems including eye drops, ophthalmic ointments, are no longer sufficient to encounter eye diseases. This article reviews the constraints with conventional ocular therapy and explores various novel approaches like in-situ gel, ocular films or ocuserts, nanosuspension, collagen shields, latex systems, nanoparticles, liposomes, niosomes, iontophorosis, eye implants, etc to improve the ophthalmic bioavailability of drugs to the anterior chamber of the eye.
Keywords:
Ophthalmic Drug Delivery, Newer Drug Delivery, Ouler Drug DeliveryDOI
https://doi.org/10.25004/IJPSDR.2009.010101References
Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-Recent Advances. Progress in Retinal and Eye Research 1998; 1733-58.
Robinson JC. Ocular anatomy and physiology relevant to ocular drug delivery. In: Mitra AK (ed), Ophthalmic Drug Delivery Systems, Marcel Dekker: New York, US, 1993, 29-57.
Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clinical and Experimental Pharmacology and Physiology 2000; 27: 558-562.
Le Bourlais CA, Treupel-Acar L, Rhodes CT, Sado PA, Leverge R. New ophthalmic drug delivery systems. Drug Development and Industrial Pharmacy 1995; 21: 19-59.
Lang JC. Ocular drug delivery conventional ocular formulations. Advanced Drug Delivery Reviews 1995; 16: 39-43.
Maurice DM. The dynamics and drainage of tears. International Ophthalmology. Clin. 1973; 13: 103-115.
Mishima S, Maurice DM. Oily layer of tear film and evaporation from corneal surface. Experimental Eye Research 1961; 1: 39-45.
Ludwig A, Van Ootenhgm M. Influence of viscolyzers on the residence of ophthalmic solutions evaluated by slit lamp fluorophotometry. S.T.P. Pharmaceutical Sciences 1992; 2: 81-87.
Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharmaceutical Research, 1991; 8: 1039-1043.
Patton TF, Robinson JR. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. Journal of Pharmaceutical Sciences 1975; 64:1312- 1315.
Robinson JR. Mucoadhesive ocular drug delivery systems. In: Gurny R and Junginger HE (eds), Bioadhesion Possibilities and Future Trends. Wissenscaftliche Verlagsgesellschaft mbH:Stuttgart, Germany, 1990, 109-123.
Zimmer AK, Chetoni P, Saettone MF, Zerbe H, Kreuter J. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers. Journal of Controlled Release, 1995; 33: 31-46.
Nicholls TJ, Cook DJ, Rogers DJ, Green KL, Smart JD. Lectins in ocular drug delivery - An in vivo study of lectin retention on ocular surfaces. Pharmaceutical Sciences 1997; 3: 1-5.
Nagarsenker MS, Londhe VY, Nadkarni CID. Preparation and evaluation of liposomal formulations of tropicamide for ocular drug delivery. International Journal of Pharmaceutics 1999; 190: 63-71.
Ding S. Recent developments in ophthalmic drug delivery. PSTT, 1998; 1: 328-335.
Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura M. Enhancement of ocular drug penetration. Critical Reviews in Therapeutic Drug Carrier Systems 1999; 16: 85-146.
Hui HW, Robinson JR. Ocular drug delivery of progesterone using a bioadhesive polymer. International Journal of Pharmaceutics 1985; 26: 203-213.
Meseuger G, Gurny R, Buri P, Rozier A, Plazonnet B. 1993. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. International Journal of Pharmaceutics 1993; 95: 229- 234.
Gurtler F, Kaltsatos V, Boisrame B, Gurny R. Long-acting soluble Bioadhesive Ophthalmic Drug Insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation. Journal of Controlled Release 1995; 33: 231-236.
O'Brien TP, Sawusch MR, Dick JD, Hamburg TR, Gottsch JD. Use of collagen corneal shields versus soft contact lenses to enhance penetration of topical tobramycin. Journal of Cataract and Refractive Surgery 1988; 14: 505-507.
Unterman SR, Rootman DS, Hill JM, Parelman JJ, Thompson HW, Kaufman HE. Collagen shield drug delivery: therapeutic concentrations of tobramycin in the rabbit cornea and aqueous humour. Journal of Cataract and Refractive Surgery 1988; 15: 500- 504.
Diestelhorst M. Grunthal S. Suverkrup R. Dry Drops: a new preservative-free drug delivery system. Graefes Archives Clinical and Experimental Ophthalmology 1999; 237: 394-398.
Simamora P, Nadkarni SR, Lee YC, Yalkowsky SH. Controlled delivery of pilocarpine. 2. In vivo evaluation of Gelfoam device. International Journal of Pharmaceutics 1998; 170: 209-214.
Bawa R. Ocular Inserts. In: Mitra AK (ed), Ophthalmic Drug Delivery Systems. Marcel Dekker Inc.: New York, US, 1993, 223- 260.
Lawrenson JG, Edgar DF, Gudgeon AC, Burns JM, Geraint M, Nas BA. Comparison of the efficacy and duration of action of topically applied proxymetacaine using a novel ophthalmic delivery system versus eye drops in healthy young volunteers. British Journal of Ophthalmology 1993; 77: 713-715. 26. Quigley HA, Pollack IP, Harbin TS. Pilocarpine ocuserts. Long term clinical trials and selected pharmacodynamics. Archives of Ophthalmology 1975; 93: 771-775.
Chetoni P, Di Colo G, Grandi M, Morelli M, Saettone MF, Darougar S. Silicone rubber/hydrogel composite ophthalmic inserts: preparation and preliminary in vitro/in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics 1998; 46: 125-132.
Published
Abstract Display: 937 
PDF Downloads: 454 How to Cite
Issue
Section
Copyright (c) 2009 K. S. Rathore, R. K. Nema
This work is licensed under a Creative Commons Attribution 4.0 International License.
